Pharmaceutical News

RSS

New drugs to combat bioterrorism

The University of Illinois at Chicago College of Pharmacy has received a grant from the U.S. Department of Defense to develop new drugs to combat agents of bioterrorism.

7 Aug 2007

FDA approves maraviroc, an antiretroviral drug for use in adult HIV patients.

The U.S. Food and Drug Administration (FDA) has approved maraviroc, an antiretroviral drug for use in adult HIV patients. Maraviroc, sold under the trade name Selzentry, is the first in a new class of drugs designed to slow the advancement of HIV and received priority review by the FDA.

7 Aug 2007

GlaxoSmithKline receives bulk H5N1 antigen order for the US national stockpile

GlaxoSmithKline has announced that HHS has placed another order to purchase bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines.

6 Aug 2007

Money for medicine

Last week, it was announced that drug addicts in England are to be given shopping vouchers for complying with treatment programmes. In this week's British Medical Journal, two experts debate whether it is acceptable for people to be paid to adhere to medication.

3 Aug 2007

FDA, DoD collaborate on regulated drugs, biologics, and medical devices

Data from the U.S. Military Health System will soon help the U.S. Food and Drug Administration make decisions affecting the safety and use of FDA-regulated products for all Americans.

3 Aug 2007

CDC to provide intravenous artesunate for treatment of severe malaria

The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.

3 Aug 2007

Benefits and risks of the new HPV vaccine aren't fully known

Media coverage of the recently introduced human papillomavirus (HPV) vaccine - including talk of state-mandated vaccination programs - has brought considerable attention, if not always clarity, to this issue.

2 Aug 2007

Genta and Emisphere Technologies file investigational new drug exemption

Genta Inc. and Emisphere Technologies, Inc. have jointly announced the submission of an Investigational New Drug Exemption (IND) to the Endocrinologic and Metabolic Drugs Division of the U.S. Food and Drug Administration (FDA) for a new drug known as G4544.

2 Aug 2007

Vaccines approved by the FDA are at least a million times safer than the viruses that they prevent

For more than 200 years, vaccines have played an important role in the prevention of infectious diseases.

2 Aug 2007

FDA Avandia recommendation welcomed by Endocrinologists

The American Association of Clinical Endocrinologists (AACE), along with the rest of the medical community, has watched with concern the debate regarding usage of GlaxoSmithKline's rosiglitazone (Avandia) in diabetes and the question of whether it increases cardiovascular risk.

1 Aug 2007

QIAGEN acquires Digene

QIAGEN completed the acquisition through a tender offer and subsequent merger of Digene with and into a wholly owned subsidiary of QIAGEN. At the completion of the merger, Digene will become a wholly owned subsidiary of QIAGEN's affiliate QIAGEN North American Holdings, Inc.

From QIAGEN Manchester Limited 1 Aug 2007

Coated aspirin doesn't guarantee problem-free use

Some people take aspirin without ever having a problem with their stomach. Others develop low-grade stomach pain or get an ulcer.

31 Jul 2007

Biota increases damages claim against GlaxoSmithKline

Australian company Biota has filed its updated Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support the influenza drug, Relenza, discovered by Biota and licensed to GSK in 1990.

31 Jul 2007

Majority of FDA panel votes in favor of Avandia

GlaxoSmithKline has welcomed the nearly unanimous recommendation of an U.S. Food and Drug Administration's (FDA) advisory committee to support Avandia's (rosiglitazone maleate) continued availability to patients in the U.S.

30 Jul 2007

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Avandia too risky says expert

One of the members of the advisory panel set up to discuss the future of the diabetes pill Avandia says it should be removed from the market because it is too risky and offers no advantage over other alternatives.

30 Jul 2007

Polypill cure-for-all could become a killer

Doctors in Britain are warning that offering all men over 50 and all women over 60 a pill to protect them against heart disease and stroke, will only serve to encourage an unhealthy lifestyle.

30 Jul 2007

Europe approves MIRCERA to treat anaemia

Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).

27 Jul 2007

Merck appoints David Kelley, M.D., to key role in growing Diabetes and Obesity franchise

Merck & Co., Inc. has announced that David E. Kelley, M.D., has been named vice president, franchise integrator for Diabetes & Obesity. Dr. Kelley joins Merck after 20 years on staff at the University of Pittsburgh, where he most recently served as professor of medicine and director of the Obesity & Nutrition Research Center.

24 Jul 2007

FDA panel will help decide fate of drug Evista for preventing breast cancer

Before the osteoporosis drug Evista is approved for breast cancer in the U.S. the Food and Drug Administration (FDA) will take the advice of an advisory panel.

23 Jul 2007